AXL and renal cell carcinoma: Preclinical studies demonstrated that tretinoin can be a novel promising drug to overcome this RCC resistance by decreasing TR4 and AXL, establishing the foundation for further testing this combination in a clinical setting to enhance sunitinib efficacy in RCC in patients.